ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

OGI vs CATX // RSI-14 & 200D SMA MOMENTUM

Organigram Global Inc. (NASDAQ) VS. Perspective Therapeutics Inc. (NYSE) • 15-METRIC TALLY: OGI 2 — CATX 0
▲ RSI-14 & 200D SMA MOMENTUM LEADER: OGI
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OGI VS. CATX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC OGI CATX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) — -35.00% — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality — 2/9 — TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 41.6 22.4 +19.20 OGI /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $131.6M $131.3M $298.8K OGI /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR OGI REV CATX REV OGI GROSS % CATX GROSS % OGI FCF CATX FCF
FY 2025 — $318.0M — — — -$95.2M
FY 2024 — $254.5M — — — -$72.7M
FY 2023 — $114.6M — — — -$36.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OGI // BETA —
CATX // BETA —